An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria

@article{Juregui2012AnOO,
  title={An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria},
  author={Ignacio J{\'a}uregui and Eduardo Garc{\'i}a-Lirio and Ana Soriano and Pedro M Gamboa and Ignacio Ant{\'e}para},
  journal={Expert Review of Clinical Immunology},
  year={2012},
  volume={8},
  pages={33 - 41}
}
Currently available second-generation H1-antihistamines include a wide group of drugs with a better therapeutic index (or risk–benefit ratio) than the classic antihistamines, although their properties and safety profiles may differ. Bilastine is a newly registered H1-antihistamine for the oral treatment of allergic rhinitis and urticaria, with established antihistaminic and antiallergic properties. Clinical studies in allergic rhinitis and chronic urticaria show that once-daily treatment with… 

Safety profile of bilastine: 2nd generation H1-antihistamines.

  • F. Scaglione
  • Medicine, Biology
    European review for medical and pharmacological sciences
  • 2012
Bilastine is a new H1 antagonist with no sedative side effects, no cardiotoxic effects, and no hepatic metabolism, and it meets the current criteria for medication used in the treatment of allergic rhinitis and urticaria.

Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving

Current evidence shows that bilastine has an optimal benefit-to-risk ratio, meeting all conditions for contributing to safety in drivers who need antihistamines, and hence for being considered as an antihistamine of choice for drivers.

The Efficacy and Safety of Bilastine in the Treatment of Perennial Allergic Rhinitis in Patients with Moderate and Severe Forms of the Disease. Comparison of bilastine 20 mg with desloratadine 5 mg Сергей

Bilastine and desloratadine showed a comparable efficacy profile in the treatment of ARC; however, the results obtained in the subgroup of patients with moderate / severe persistent symptoms indicate that bilastine has a stronger therapeutic effect.

Bilastine for the treatment of chronic spontaneous urticaria: Consensus statement for Indian patients

  • K. GodseA. De Mu
  • Medicine
    IP Indian Journal of Clinical and Experimental Dermatology
  • 2021
Bilastine, a second generation H1-antihistamine, offers significant benefits over most antihistamines including once daily dosage, significant efficacy in relieving symptom, minimal risk of drug to drug interactions and adverse events.

The role and choice criteria of antihistamines in allergy management – expert opinion

A panel of experts gathered the latest data from the entire scientific literature and analysed the latest standards and recommendations prepared by scientific societies to highlight the importance for the patient of the proper choice of drug to treat his allergies.

Allergic diseases in the elderly: biological characteristics and main immunological and non-immunological mechanisms

The state of the art on the physiological changes in the elderly responsible for allergic diseases, their biological characteristics and the major immunological and extra immunological mechanisms are provided.

Эффективность и безопасность биластина в лечении круглогодичного аллергического ринита у пациентов со среднетяжелыми и тяжелыми формами заболевания

Bilastine and desloratadine showed a comparable efficacy profile in the treatment of ARC; however, the results obtained in the subgroup of patients with moderate / severe persistent symptoms indicate that bilastine has a stronger therapeutic effect.

Adverse effects of antihistamines portal vein inferior vena cava aorta hepatic artery gall bladder common bile duct

Address for correspondence: Prof. Piotr Kuna MD, PhD, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Faculty of Medicine, Medical University of Lodz, 22 Kopcinskiego

References

SHOWING 1-10 OF 45 REFERENCES

Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria

  • M. Church
  • Medicine
    Expert opinion on drug safety
  • 2011
Bilastine has high selectivity for H1-receptors, is rapidly and effectively absorbed, undergoes negligible metabolism and is a substrate for P-glycoprotein, which limits its passage across the blood–brain barrier.

The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber

Bilastine, like cetirizine and fexofenadine, was safe and well tolerated in this study and had a rapid onset of action within 1 h, and a long duration of action, greater than 26 h.

Central effects of H1 and H2 antihistamines.

Tests on the central effects of H1 and H2 antagonists are reviewed, and tentative recommendations are made in respect of these findings concerning the possible use of these drugs in aircrew.

Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients

The objective of this study was to compare the efficacy and safety of bilastine 20 mg vs placebo and desloratadine 5’mg in subjects with seasonal allergic rhinitis (SAR).

Urticaria: current opinions about etiology, diagnosis and therapy.

For symptomatic relief, non-sedating H1-antihistamines are the first choice in most subtypes of urticaria; however, double-blind controlled studies have shown that the dosages required may exceed those recommended for other diseases, e.g. allergic rhinitis.

Progress and Challenges in the Understanding of Chronic Urticaria

  • M. FerrerA. Kaplan
  • Medicine, Biology
    Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
  • 2007
Basophils of all chronic urticaria patients (autoimmune or idiopathic) are hyperresponsive to serum, regardless of source, but poorly responsive to anti IgE.

Cardiac actions of antihistamines.

  • R. Woosley
  • Medicine, Biology
    Annual review of pharmacology and toxicology
  • 1996
Two of the nonsedating antihistaminic drugs, terfenadine and astemizole, have recently been recognized in rare cases to induce the syndrome of torsades de pointes, i.e. QT interval prolongation and

In Vivo Pharmacological Characterisation of Bilastine, a Potent and Selective Histamine H1 Receptor Antagonist

In vivo preclinical studies corroborate those obtained from previously conducted in vitro experiments of bilastine, and provide evidence that bilastines possesses antihistaminic as well as antiallergic properties, with similar potency to cetirizine and superior potency to fexofenadine.

Advances in H1-antihistamines.

  • F. Simons
  • Medicine, Biology
    The New England journal of medicine
  • 2004
There are clinically relevant differences among H1-antihistamines in their pharmacology and safety profiles in allergic rhinoconjunctivitis and chronic urticaria.

Bilastine and the central nervous system.

Bilastine is a new H1 antihistamine that proves to be effective in treating allergic rhinoconjunctivitis (seasonal and perennial) and urticaria and is defined as a clinically promising drug with a good safety profile as regards adverse effects upon the central nervous system.